Luminoma Diagnostics
University of Auckland spin-out developing LumAssure, a portable device that fires a laser at a suspicious skin lesion and classifies its Raman spectral fingerprint with machine learning to distinguish malignant from benign in about ten seconds, targeting melanoma and keratinocyte cancers.
Headquarters
Auckland, New Zealand
Year Founded
2023
Founders
Maher Khaled (CEO and co-founder), Michel Nieuwoudt, Cather Simpson
Country
New Zealand
Financial Information
Funding Stage
Seed
Recent Funding
NZ$3.9M
Funding By
Bridgewest Ventures, Pacific Channel, UniServices (University of Auckland Inventors Fund)
Core Technology
Raman spectroscopy with machine-learning chemometric classification
Product Type
Medical Device
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: N/A
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
University of Auckland Photon Factory (spin-out origin)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Ten-second optical lesion assessment without biopsy, designed for primary care